## **Clifford M Takemoto**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3751766/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature, 1998, 391, 298-301.	27.8	588
2	Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines. Pediatrics, 2010, 126, 746-759.	2.1	503
3	The genomic landscape of juvenile myelomonocytic leukemia. Nature Genetics, 2015, 47, 1326-1333.	21.4	233
4	Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood, 2015, 125, 1470-1476.	1.4	184
5	Lineage-specific Signaling in Melanocytes. Journal of Biological Chemistry, 1998, 273, 17983-17986.	3.4	174
6	Diagnostic utility of telomere length testing in a hospital-based setting. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2358-E2365.	7.1	165
7	Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. Human Molecular Genetics, 2000, 9, 125-132.	2.9	150
8	Linkage of M-CSF Signaling to Mitf, TFE3, and the Osteoclast Defect in Mitfmi/mi Mice. Molecular Cell, 2001, 8, 749-758.	9.7	145
9	Association of Perioperative Red Blood Cell Transfusions With Venous Thromboembolism in a North American Registry. JAMA Surgery, 2018, 153, 826.	4.3	133
10	Hospital-Associated Venous Thromboembolism in Children: Incidence and Clinical Characteristics. Journal of Pediatrics, 2014, 164, 332-338.	1.8	112
11	Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatric Blood and Cancer, 2008, 50, 1006-1012.	1.5	97
12	Age-resolving Osteopetrosis: A Rat Model Implicating Microphthalmia and the Related Transcription Factor TFE3. Journal of Experimental Medicine, 1998, 187, 775-785.	8.5	88
13	Activated Partial Thromboplastin Time and Anti-Xa Measurements in Heparin Monitoring. American Journal of Clinical Pathology, 2013, 139, 450-456.	0.7	78
14	The Identification and Functional Characterization of a Novel Mast Cell Isoform of the Microphthalmia-associated Transcription Factor. Journal of Biological Chemistry, 2002, 277, 30244-30252.	3.4	71
15	KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. Blood, 2011, 117, 3629-3640.	1.4	60
16	Development of a New Risk Score for Hospital-Associated Venous Thromboembolism in Noncritically Ill Children: Findings from a Large Single-Institutional Case-Control Study. Journal of Pediatrics, 2014, 165, 793-798.	1.8	60
17	Risk factors for hospital-sssociated venous thromboembolism in the neonatal intensive care unit. Thrombosis Research, 2014, 134, 305-309.	1.7	59
18	Iron Status is Associated with Asthma and Lung Function in US Women. PLoS ONE, 2015, 10, e0117545.	2.5	52

#	Article	IF	CITATIONS
19	Development of a new risk score for hospital-associated venous thromboembolism in critically-ill children not undergoing cardiothoracic surgery. Thrombosis Research, 2015, 136, 717-722.	1.7	50
20	Distinct and Shared Transcriptomes Are Regulated by Microphthalmia-Associated Transcription Factor Isoforms in Mast Cells. Journal of Immunology, 2007, 178, 378-388.	0.8	39
21	SHP-1 Deficient Mast Cells Are Hyperresponsive to Stimulation and Critical in Initiating Allergic Inflammation in the Lung. Journal of Immunology, 2010, 184, 1180-1190.	0.8	38
22	Pediatric Hospital Acquired Venous Thromboembolism. Frontiers in Pediatrics, 2017, 5, 198.	1.9	37
23	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 129.	7.4	37
24	Venous thromboembolism in cystic fibrosis. Pediatric Pulmonology, 2012, 47, 105-112.	2.0	36
25	Approach to pancytopenia: Diagnostic algorithm for clinical hematologists. Blood Reviews, 2018, 32, 361-367.	5.7	35
26	Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B. Pediatric Nephrology, 1998, 12, 654-657.	1.7	31
27	The p85α Subunit of Class I <sub>A</sub> Phosphatidylinositol 3-Kinase Regulates the Expression of Multiple Genes Involved in Osteoclast Maturation and Migration. Molecular and Cellular Biology, 2008, 28, 7182-7198.	2.3	31
28	Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatric Blood and Cancer, 2007, 49, 1025-1029.	1.5	29
29	Mast cell transcriptional networks. Blood Cells, Molecules, and Diseases, 2008, 41, 82-90.	1.4	29
30	How we approach thrombosis risk in children with COVID″9 infection and MIS . Pediatric Blood and Cancer, 2021, 68, e29049.	1.5	25
31	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513.	7.4	24
32	Effectiveness of surgical revascularization for stroke prevention in pediatric patients with sickle cell disease and moyamoya syndrome. Journal of Neurosurgery: Pediatrics, 2017, 20, 232-238.	1.3	23
33	Thrombotic disease in critically ill children. Pediatric Critical Care Medicine, 2011, 12, 80-89.	0.5	20
34	Risk factors for hospital-associated venous thromboembolism in critically ill children following cardiothoracic surgery or therapeutic cardiac catheterisation. Cardiology in the Young, 2018, 28, 234-242.	0.8	20
35	SHP-1 Regulation of Mast Cell Function in Allergic Inflammation and Anaphylaxis. PLoS ONE, 2013, 8, e55763.	2.5	19
36	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 528-541.	2.3	18

#	Article	IF	CITATIONS
37	Heparin-Induced Thrombocytopenia Screening and Management in Pediatric Patients. Hematology American Society of Hematology Education Program, 2011, 2011, 162-169.	2.5	17
38	Balanced Interactions between Lyn, the p85Â Regulatory Subunit of Class IA Phosphatidylinositol-3-Kinase, and SHIP Are Essential for Mast Cell Growth and Maturation. Molecular and Cellular Biology, 2011, 31, 4052-4062.	2.3	17
39	Kaposiform lymphangiomatosis treated with multimodal therapy improves coagulopathy and reduces blood angiopoietinâ€2 levels. Pediatric Blood and Cancer, 2020, 67, e28529.	1.5	17
40	Dâ€dimer for the diagnosis of venous thromboembolism in children. American Journal of Hematology, 2009, 84, 62-63.	4.1	16
41	Genetic Evidence for Critical Roles of P38α Protein in Regulating Mast Cell Differentiation and Chemotaxis through Distinct Mechanisms. Journal of Biological Chemistry, 2012, 287, 20258-20269.	3.4	15
42	PU.1 Positively Regulates GATA-1 Expression in Mast Cells. Journal of Immunology, 2010, 184, 4349-4361.	0.8	14
43	Current and future treatment approaches for Barth syndrome. Journal of Inherited Metabolic Disease, 2022, 45, 17-28.	3.6	14
44	Computerized Physician Order Entry Improves Compliance With a Manual Exchange Transfusion Protocol in the Pediatric Intensive Care Unit. Journal of Pediatric Hematology/Oncology, 2014, 36, 143-147.	0.6	13
45	Safety and efficacy of catheter directed thrombolysis in children with deep venous thrombosis. British Journal of Haematology, 2012, 159, 376-378.	2.5	11
46	High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. Journal of Pediatric Hematology/Oncology, 2016, 38, 627-635.	0.6	11
47	Mortality Associated with Venous Thromboembolism in Hospitalized Pediatric Patients: A Single Tertiary Care Institute Experience. Blood, 2015, 126, 629-629.	1.4	10
48	CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. Blood Advances, 2022, 6, 521-527.	5.2	10
49	Germline Gain-of-Function <i>JAK3</i> Mutation in Familial Chronic Lymphoproliferative Disorder of NK Cells. Blood, 2020, 136, 9-10.	1.4	9
50	Challenges in the management of the transgender patient with sickle cell disease. American Journal of Hematology, 2018, 93, E360-E362.	4.1	7
51	Correlates of successful transition in young adults with sickle cell disease. Pediatric Blood and Cancer, 2019, 66, e27939.	1.5	7
52	The Clinical Utility of the Heparin Neutralization Assay in the Diagnosis of Heparin-Induced Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 749-754.	1.7	4
53	Thrombosis with COVID-19: kids get it too. Blood, 2021, 138, 109-111.	1.4	4
54	A Large Ribosomal Subunit Protein Abnormality in Diamond-Blackfan Anemia (DBA) Blood, 2007, 110, 422-422.	1.4	4

#	Article	IF	CITATIONS
55	Immune thrombocytopenia due to Trimethoprim‣ulfamethoxazole; underâ€recognized adverse drug reaction in children?. Pediatric Blood and Cancer, 2015, 62, 922-923.	1.5	3
56	Diagnosis of congenital and acquired focal lesions in the neck, abdomen, and pelvis with contrast-enhanced ultrasound: a pictorial essay. European Journal of Pediatrics, 2018, 177, 1459-1470.	2.7	3
57	Kit Signaling Regulates Mitf Expression in Mastocytosis Blood, 2006, 108, 3601-3601.	1.4	3
58	Mortality and Associated Comorbidities Among Patients Hospitalized for Deep Vein Thrombosis and Pulmonary Embolism in the United States: Results from a Nationally Representative Database. Blood, 2020, 136, 39-40.	1.4	3
59	A Risk-Prediction Model For Identifying Venous Thromboembolism In Hospitalized Pediatric Patients: A Single Institution Retrospective Case-Control Analysis. Blood, 2013, 122, 2957-2957.	1.4	2
60	Rituximab for ITP: A longâ€ŧerm fix?. Pediatric Blood and Cancer, 2009, 52, 155-156.	1.5	1
61	Lack of Inhibitor Development in the American Thrombosis and Hemostasis Network (ATHN)-2 Factor Switching Study: Preliminary Report of Primary Outcome. Blood, 2019, 134, 1114-1114.	1.4	1
62	Lymphadenopathy as the primary manifestation of malignant transformation in two patients with severe congenital neutropenia. Pediatric Blood and Cancer, 2008, 50, 1072-1075.	1.5	0
63	Mast Cells—Friend or Foe?. Journal of Pediatric Hematology/Oncology, 2010, 32, 342-344.	0.6	0
64	Reduced intensity chemotherapy with tyrosine kinase inhibitor and blinatumomab in a pediatric patient with Philadelphia chromosomeâ€positive ALL and mechanical heart valves. Pediatric Blood and Cancer, 2021, 68, e28924.	1.5	0
65	Transcriptional Regulation of a Distinct GATA-1 Isoform during Selection of the Mast and Erythroid Lineages Blood, 2004, 104, 1600-1600.	1.4	0
66	Heparin Induced Thrombocytopenia in Pediatric Patients: Utility of Laboratory Testing. Blood, 2011, 118, 1171-1171.	1.4	0
67	First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol,) Tj ETQq1 1 0.	784314 rg 1.4	BT/Overlock
68	Liposome-Encapsulated Cytarabine and Daunorubicin (CPX-351) Induces Remission in Newly Diagnosed Pediatric Secondary Myeloid Malignancies. Blood, 2021, 138, 4415-4415.	1.4	0
69	Von Willebrand Disease. Pediatrics in Review, 2014, 35, 136-137.	0.4	0
70	Risk Factors and Cardiovascular Disease (CVD) Related Outcomes in Hospitalized Patients with Hemophilia 10 Year Follow up. Blood, 2020, 136, 30-31.	1.4	0
71	Introduction: The changing role of the pediatric hematologist/oncologist in the care of people with vascular anomalies. Pediatric Blood and Cancer, 2022, , e29614.	1.5	0